Amplia Therapeutics Limited (INNMF)

OTCMKTS · Delayed Price · Currency is USD
0.1470
0.00 (0.00%)
Jul 2, 2025, 4:00 PM EDT
210.13%
Market Cap 75.10M
Revenue (ttm) 2.36M
Net Income (ttm) -4.10M
Shares Out n/a
EPS (ttm) -0.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 3,000
Average Volume 17,551
Open 0.1680
Previous Close 0.1470
Day's Range 0.1470 - 0.1680
52-Week Range 0.0281 - 0.1778
Beta 0.38
RSI 70.06
Earnings Date Aug 27, 2025

About Amplia Therapeutics

Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in 1b/2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications. The company was formerly known as Innate Immunotherapeutics Limited and changed... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Country Australia
Stock Exchange OTCMKTS
Ticker Symbol INNMF
Full Company Profile

Financial Performance

In 2024, Amplia Therapeutics's revenue was 3.78 million, a decrease of -15.03% compared to the previous year's 4.45 million. Losses were -6.57 million, 45.9% more than in 2023.

Financial numbers in AUD Financial Statements

News

There is no news available yet.